Article citationsMore>>

Montanari, L., Alfei, A., Albonico, G., Moratti, R., Arossa, A., Beneventi, F. and Spinillo, A. (2009) The Impact of First-Trimester Serum Free Beta-Human Chorionic Gonadotropin and Pregnancy-Associated Plasma Protein A on the Diagnosis of Fetal Growth Restriction and Small for Gestational Age Infant. Fetal Diagnosis and Therapy, 25, 130-135.

has been cited by the following article:

• TITLE: Maternal PAPP-A Levels at 11 - 13 Weeks of Gestation Predict Foetal and Neonatal Growth

  AUTHORS: M. Gentile, M. Schifano, S. Lunardi, C. Nanini, F. Moscuzza, C. Sergiampietri, M. Ciantelli, F. Monacci, A. Boldrini, C. Luchi, P. Ghirri

  KEYWORDS: Maternal Predictors, Foetal Growth, Neonatal Outcome

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.5 No.6, June 24, 2015

  ABSTRACT: Recent reports suggest that maternal serum levels of pregnancy-associated plasma protein A (PAPP-A) may predict perinatal outcome. PAPP-A is a syncytiotrophoblast derived protease for insulin-like growth factor binding protein (IGFBP4); its protease activity cleaves complexed growth factor binding protein increasing insulin-like growth factor I (IGF-I) bioavailability. The aim of our study was to evaluate the correlation between maternal PAPP-A serum levels and neonatal growth. We analysed 100 full term and preterm (30 - 36 weeks) small for gestational age (SGA) and adequate for gestational age (AGA) babies whose mothers had been tested for serum PAPP-A at 11 - 13 weeks of gestation. We found a significant positive correlation between maternal PAPP-A and neonatal weight, length, and head circumference at birth in both term and preterm infants. Low maternal PAPP-A serum levels (maternal PAPP-A